<ѻýҕl>FCR Still an Option in IGHV-Unmutated CLL?ѻýҕl> Gene signature identifies lower-risk group with greater chemoimmunotherapy benefit Oct 08, 2019
<ѻýҕl>First-Line Combo Boosts PFS in Untreated Bladder Cancerѻýҕl> 'Clinically meaningful' trend in OS with atezolizumab-chemotherapy Oct 03, 2019
<ѻýҕl>In Memory of Gerald Chodak, MDѻýҕl> Pioneer of active surveillance for men with low-risk prostate cancer died last week Oct 03, 2019
<ѻýҕl>New Standard in Third-Line Metastatic CRPCѻýҕl> Cabazitaxel tops more anti-androgen in patients with "short-ish" response to abiraterone or enzalutamide Oct 01, 2019
<ѻýҕl>Novel CDK 4/6 Inhibitor Fails in Triple Negative Breast Cancerѻýҕl> Misses primary endpoints but has unexpected key benefit Oct 01, 2019
<ѻýҕl>Neoadjuvant Anti-PD-1 Boosts pCR in TNBCѻýҕl> Favorable trend toward improved event-free survival in preliminary analysis Sep 30, 2019
<ѻýҕl>Trametinib Tx Shows Promise in Tough-to-Treat LGSOCѻýҕl> Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer Sep 30, 2019
<ѻýҕl>Data Support 'Best Drug First' in EGFR-Mutant NSCLCѻýҕl> Six-month survival gain with osimertinib, adding to PFS, safety advantages Sep 29, 2019
<ѻýҕl>CDK 4/6 Inhibitors Boost OS in Advanced Breast Cancerѻýҕl> Abemaciclib, ribociclib should become first-line treatment in HR-positive/HER2-negative disease, expert says Sep 29, 2019
<ѻýҕl>PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Ca?ѻýҕl> PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines Sep 29, 2019
<ѻýҕl>Abemaciclib Offers Hope in HR+/HER2+Breast Cancerѻýҕl> Phase II monarcHER trial shows better PFS with abemaciclib-trastuzumab-fulvestrant Sep 29, 2019
<ѻýҕl>First-Line Combo Boosts PFS in Advanced Ovarian Caѻýҕl> Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup Sep 28, 2019
<ѻýҕl>Advanced HCC Trial Misses OS Endpointѻýҕl> But CheckMate 459 researchers tout "encouraging efficacy and favorable safety profile" Sep 28, 2019
<ѻýҕl>Notable OS Gains with Dual Immunotherapy in Advanced NSCLCѻýҕl> Secondary analysis of CheckMate 227 brings more good news for nivolumab-ipilimumab combo Sep 28, 2019
<ѻýҕl>BCG Vax: A Shot Against Lung Cancer in Native Populations?ѻýҕl> 60-year follow-up data from a vaccine trial found surprising results Sep 25, 2019
<ѻýҕl>Ibrutinib's Cardiotoxicity Comes Into Focusѻýҕl> Study identifies new cardiac events linked to so-called targeted therapy Sep 25, 2019
<ѻýҕl>How Often Does MRI Miss the Mark in Prostate Ca?ѻýҕl> Retrospective study finds 21% of patients with prostate cancer pathology did not have ROI on MRI Sep 25, 2019
<ѻýҕl>Red Cell Distribution Width Strongly Predicts Hip Fractureѻýҕl> Simple way to identify at-risk patients Sep 24, 2019
<ѻýҕl>Wires or RFID Tags in Breast Cancer Excision?ѻýҕl> Women like the less obtrusive method, but small study doesn't quite settle question of whether there's a tradeoff Sep 24, 2019
<ѻýҕl>ASTRO Unveils First RT Guideline for Pancreatic Cancerѻýҕl> Radiation's role in pancreatic cancer is "controversial," says guideline author Sep 23, 2019
<ѻýҕl>H. Pylori Found in Sleeve Gastrectomy Specimensѻýҕl> Incidental findings can have important clinical implications in obese patients Sep 23, 2019
<ѻýҕl>Tx Deintensification Wins in Head and Neck Cancer, But ...ѻýҕl> Only against another less-intensive approach in HPV-positive disease Sep 18, 2019
<ѻýҕl>Could Mom's Anemia Hurt Baby's Brain?ѻýҕl> Association study suggests an increased risk, though still quite small Sep 18, 2019
<ѻýҕl>Gandalf the Grey, the Wizard of Omaha, and Prostate Cancerѻýҕl> High-profile celebs and low-risk disease Sep 18, 2019
<ѻýҕl>Post-Immunotherapy SBRT Boosts Outcomes in Advanced NSCLCѻýҕl> Increased systemic response rate, disease control rate, and PFS in phase II trial Sep 17, 2019
<ѻýҕl>Consider PSA Before Adding ADT to Salvage Radiationѻýҕl> Men with levels below 0.6 ng/mL show no benefit, at risk of other-cause mortality Sep 16, 2019
<ѻýҕl>Medical Marijuana Overdose Sends Man to ERѻýҕl> Case report highlights risks of high-strength THC products in patients' hands Sep 12, 2019
<ѻýҕl>Good News, Bad News for CRISPR Gene Editing for HIV Cureѻýҕl> "Bigger story for the gene-editing field than the HIV field" Sep 11, 2019
<ѻýҕl>Anti-PD-1/L1 for NSCLC Sparks Talk of the 'C' Wordѻýҕl> Unprecedented survival at 3 and 5 years, but investigators reluctant to say "cure" Sep 10, 2019
<ѻýҕl>'Dirtier' Drugs Step Aside in RET-Positive NSCLCѻýҕl> Over two-thirds of patients respond to selective RET inhibitor Sep 09, 2019
<ѻýҕl>TMB in Lung Cancer: 'Not Ready for Prime Time'ѻýҕl> No association between tumor mutational burden and outcomes in three trials Sep 09, 2019
<ѻýҕl>The Legacy of Henry Lynch, MDѻýҕl> Earlier this summer the legendary researcher passed, his contributions to cancer research are immeasurable Sep 01, 2019
<ѻýҕl>Good News on Nipple-Sparing Breast Surgeryѻýҕl> Korean study examined recurrence rates Aug 30, 2019
<ѻýҕl>Peter Fonda’s Lung Cancer Battleѻýҕl> Farewell, Easy Rider: legendary actor dead at 79 Aug 29, 2019
<ѻýҕl>Mystery! The Vanishing Prostate Tumorѻýҕl> Do cancers really disappear spontaneously? Or are they just eluding us? Aug 23, 2019
<ѻýҕl>Olivia Newton-John's Stage 4 Cancer Cannabis Managementѻýҕl> The singer and actress updates fans on her battle, but can marijuana help? Aug 22, 2019
<ѻýҕl>Total Chemo Dose Still Matters in Breast Cancerѻýҕl> Worse survival with cumulative dose Aug 20, 2019
<ѻýҕl>When Medicare Stops Covering a Test Without Warningѻýҕl> Why didn't someone tell me, asks Hans Duvefelt, MD Aug 20, 2019
<ѻýҕl>Newer Prostate Cancer Agents Not Free of Heart Riskѻýҕl> Patients with three or more cardiac conditions were at highest risk of early death Aug 14, 2019